Erratum: Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma-a Pediatric Brain Tumor Consortium study ((Neuro-Oncology (2012) 14:11 (1404-1412) DOI: 10.1093/neuonc/nos213);Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma-a pediatric brain tumor consortium study

Neuro-Oncology

Volumn 14, Issue 11, 2012, Pages 1404-1412

  Gururangan, Sridharan ^a   Fangusaro, Jason ^b   Young Poussaint, Tina ^c   Onar Thomas, Arzu ^f   Gilbertson, Richard J ^d   Vajapeyam, Sridhar ^c   Gajjar, Amar ^d   Goldman, Stewart ^b   Friedman, Henry S ^a   Packer, Roger J ^e   Boyett, James M ^f   Kun, Larry E ^d,f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f Operations and Biostatistics Center for the Pediatric Brain Tumor Consortium   (United States)

Author keywords

bevacizumab; CPT 11; efficacy; ependymoma; recurrent

Indexed keywords

EID: 84868029000     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos318     Document Type: Erratum

References (36)

1. Mclendon R, Ng HK, Gururangan S, et al. Ependymoma, NOS, in PubCan2010, International Agency for Research on Cancer (IARC). Lyon, France: World Health Organization (WHO).
2. Bouffet E, Tabori U, Huang A, et al. Ependymoma: lessons from the past, prospects for the future. Childs Nerv Syst. 2009;25(11):1383-1384; author reply 1385.
3. Merchant TE. Current management of childhood ependymoma. Oncology (Williston Park). 2002;16(5):629-642, 644; discussion 645-6, 648.
4. Merchant TE, Boop FA, Kun LE, et al. A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys. 2008;71(1):87-97.
5. Bouffet E, Capra M, Bartels U. Salvage chemotherapy for metastatic and recurrent ependymoma of childhood. Childs Nerv Syst. 2009;25(10):1293-1301.
6. Johnson R, Wright KD, Gilbertson RJ. Molecular profiling of pediatric brain tumors: insight into biology and treatment. Curr Oncol Rep. 2009;11(1):68-72.
7. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273-286.
8. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. 2000;19(49):5598-5605.
9. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841-844.
10. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328-335.
11. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
12. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
13. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol. 2002;58(3): 255-270.
14. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253-1259.
15. Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28(18):3069-3075.
16. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26(2):271-278.
17. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17(5):1516-1525.
18. Macdonald DR, Cascino TL, Schold SC, Jr., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
19. Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist. 2007;12(3):356-361.
20. Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14(11):1131-1138.
21. Summers J, Cohen MH, Keegan P, et al. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist. 2010;15(1):104-111.
22. Jain RK. Lessons from multidisciplinary translational trials on antiangiogenic therapy of cancer. Nat Rev Cancer. 2008;8(4):309-316.
23. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69-82.
24. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5): 740-745.
25. Korshunov A, Witt H, Hielscher T, et al. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol. 2010;28(19): 3182-3190.
26. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res. 2008; 14(20):6371-6375.
27. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592-603.
28. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91(3): 329-336.
29. Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008;26(24):4037-4038.
30. Disel U, Besen AA, Ozyilkan O, et al. A case report of bevacizumabrelated osteonecrosis of the jaw: Old problem, new culprit. Oral Oncol. 2012;48:e2-3.
31. Hamstra DA, Galban CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26(20):3387-3394.
32. Pope WB, Lai A, Mehta R, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumabtreated glioblastoma. AJNR Am J Neuroradiol. 2011;32(5):882-889.
33. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83-95.
34. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27(18):3020-3026.
35. Atkinson JM, Shelat AA, Carcaboso AM, et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell. 2011;20(3):384-399.
36. Johnson RA, Wright KD, Poppleton H, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature. 2010;466(7306):632-636.